Drone raid razes Indian‑linked drug manufacturing hub
New Delhi. A Russian‑operated drone slammed into the Kusum Group’s production complex in Sumy, Ukraine, leveling the main structure, killing an engineer and wounding multiple staff members. The strike hit the plant repeatedly, demolishing the engineering wing and triggering an emergency evacuation of the premises.
Early estimates place the material loss at about Rs 400 crore, although the firm says a comprehensive audit is still pending. With such extensive destruction, the site is expected to stay out of operation for an undefined period.
Indian origins, Ukrainian presence
Kusum Group first entered the Ukrainian market in 1994, initially acting as a distributor of medicines sourced from India. By 2009 it had erected a full‑scale manufacturing campus in Sumy, complementing its 2007 production base in India. Today the conglomerate produces more than 50 generic medicines and supplies pharmacies across Ukraine, Uzbekistan, Kazakhstan and the Philippines, positioning itself as a Ukrainian pharma company with Indian roots.
Production persisted through war – until now
Despite the ongoing conflict, the Sumy plant continued to churn out essential drugs for patients locally and regionally. The latest drone attack, however, has forced a complete shutdown and pushed the group to consider rerouting vulnerable output to its facilities in India.
Ukrainian President Volodymyr Zelenskyy denounced the incident, confirming that a coordinated drone barrage targeted the pharmaceutical complex and resulted in a death. The episode highlights the growing peril faced by civilian and commercial infrastructure in active war zones.
Broader implications
The loss of the Sumy plant threatens the availability of critical generic medicines in the region and raises serious doubts about the durability of cross‑border supply chains amid armed conflict. A thorough post‑incident review will gauge the full financial and operational impact on the Indian‑linked enterprise.
